Evaluating neuroinflammation in patients with Multiple System Atrophy using PET imaging
TSPO PET in the Evaluation of Neuroinflammation in Patients with Multiple System Atrophy
This study is testing if special brain scans can help understand inflammation in the brains of people with Multiple System Atrophy to improve diagnosis and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 35 Years to 80 Years |
| Sex | All |
| Sponsor | Central South University Academic / other |
| Locations | 1 site (Hunan, Changsha) |
| Trial ID | NCT06890390 on ClinicalTrials.gov |
What this trial studies
This observational study aims to utilize PET/MR imaging techniques that target TSPO to investigate the changes in neuroinflammation associated with Multiple System Atrophy (MSA). It focuses on both the cerebellar and parkinsonian subtypes of MSA, assessing the potential of neuroinflammation as a biomarker for diagnosing, determining disease severity, and predicting prognosis. The study includes patients aged over 35 who have been clinically diagnosed with MSA and have ruled out other genetic conditions. Participants will undergo neuroimaging to gather data on the temporal and spatial characteristics of neuroinflammation in MSA.
Who should consider this trial
Good fit: Ideal candidates are individuals over 35 years old with clinically confirmed or probable MSA who have excluded polyQ diseases.
Not a fit: Patients who are pregnant, breastfeeding, or have other neurological disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance diagnostic accuracy and treatment strategies for patients with Multiple System Atrophy.
How similar studies have performed: While the approach of using PET imaging for neuroinflammation is established, the specific application to MSA is relatively novel and less explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age\> 35 years old, gender is not limited; * Clinically confirmed MSA and clinically probable MSA according to the 2022 MDS MSA diagnostic criteria; * all patients had been ruled out of polyQ disease by genetic testing; * Voluntarily participate in this study and sign the informed consent form. Exclusion Criteria: * pregnancy or breastfeeding; * contraindications to MRI examination or inability to cooperate in completing neuroimaging examination; * previous history of other neurological disorders or presence of other organic intracranial lesions on neuroimaging that cannot be interpreted by MSA, such as epilepsy, trauma, tumors, or high-grade cerebral white matter degeneration (Fazekas grade 2 and above); * History of alcohol or drug abuse
Where this trial is running
Hunan, Changsha
- Third Xiangya Hospital of Central South University — Hunan, Changsha, China (Recruiting)
Study contacts
- Study coordinator: He RQ 何
- Email: hrq1234562001@163.COM
- Phone: 0086 186 2214 8869
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.